Page 72 - Magyar Gasztroenterológiai Társaság 2020. november 6–7. – ONLINE KONGRESSZUS

Előadáskivonatok / Abstracts

Következtetések: Már a szubdózisú, a kellőnél rövidebb mg subcutaneous injection from week 8 as a maintenance
Következtetések: Már a szubdózisú, a kellőnél rövidebb mg subc Our primary endpoint was clinical
ideig alkalmazott VSL3# kezelés is enyhítheti a CU
therapy. utaneous injection from week 8 as a maintenance
ideig alkalmazott VSL3# kezelés is enyhítheti a CU therapy. Our primary endpoint was clinical
lefolyását. A konzervatív kezelésre nem reagáló, aktív
response/remission at week 16/20 and 32, defined as a
reduction of ≥70 in Crohn Disease Activity Index (CDAI) a
lefolyását. A konzervatív kezelésre nem reagáló, aktív response/remission at week 16/20 and 32, defined as
tüneteket produkáló CU-s betegek számára a VSL#3
reduction of ≥70 in Crohn Disease Activity Index (CDAI)
tüneteket produkáló CU-s betegek számára a VSL#3 and/or a CDAI which is 150 or lower. The secondary endpoint
hatékony kiegészítő kezelés lehet a tünetek és a betegség
and/or a CDAI which is 150 or lower. The secondary endpoint
hatékony kiegészítő kezelés lehet a tünetek és a betegség was to correlate serum UST and anti-UST concentrations
aktivitásának csökkentésére. A vizsgálat limitációi a kis
with clinical and biochemical activity.
aktivitásának csökkentésére. A vizsgálat limitációi a kis was to correlate serum UST and anti-UST concentrations
esetszám, a betegség kiterjedtségének heterogenitása, a
Results: Sixty-one patients receive UST in our Department
placebo kar hiánya, a rövid ideig alkalmazott és a with clinical and biochemical activity.
esetszám, a betegség kiterjedtségének heterogenitása,
placebo kar hiánya, a [mean age: 40.2 years, SD: 13.5 years, male/female ratio:
szuboptimális dózisú kezelés. rövid ideig alkalmazott és
Results: Sixty-one patients receive UST in our Department
szuboptimális dózisú kezelés. 23/38]. Twelve, ten, twenty-five and eleven patients
[mean age: 40.2 years, SD: 13.5 years, male/female ratio:
completed week 8, 16, 32 and 52, respectively. UST was

98. HIGH POLYP DETECTION RATE DURING 23/38]. Twelve, ten, twenty-five and eleven patients
COLORECTAL CANCER SCREENING RATE
98. HIGH POLYP DETECTION DURING completed week 8, 16, 32 and 52, respectively. UST was
stopped in four patients due to loss of response, in one
1
patient due to pregnancy. Fifty-two point four% of the
1
1
Mohácsi S. , Dubravcsik Z. , Budai A. , Szajki K. , Szepes
COLORECTAL CANCER SCREENING 2 stopped in four patients due to loss of response, in one
patient due to pregnancy. Fifty-two point four% of the
2
1
1
1
A. , Velkei T. , Virányi Z. , Erdélyi B. , Farkas-Rusu E. ,
Mohácsi S. , Dubravcsik Z. , Budai A. , Szajki K. , Szepes patients required dose-escalation, 34.4% receive UST in
1
1
11
1
1
1
1
1
every 8 weeks, 18% receive it in every 4 weeks. CRP
Lassú P. , Novák P. 1 1 1 patients required dose-escalation, 34.4% receive UST in
A. , Velkei T. , Virányi Z. , Erdélyi B. , Farkas-Rusu E. ,
Lassú P. , Novák P.
1. BKM Hospital, Gastroenterology and OMCH Endoscopy every 8 weeks, 18% receive it in every 4 weeks. CRP
1
1
decreased significantly at week 16/20, however no difference
Center, Kecskemét; 2. BKM Hospital, Surgery and OMCH
1. BKM Hospital, Gastroenterology and OMCH Endoscopy decreased significantly at week 16/20, however no difference
was observed in CRP values at week 32 (p < 0.05 and p =
0.13, respectively). Clinical response was observed in 2 and
Center, Kecskemét; 2. BKM
Endoscopy Center, Kecskemét Hospital, Surgery and OMCH was observed in CRP values at week 32 (p < 0.05 and p =
Endoscopy Center, Kecskemét 0.13, respectively). Clinical response was observed in 2 and
1 patients at week 16/20 and 32. Remission was observed in
Introduction : Polyps or tumors are frequently found during 1 patients at week 16/20 and 32. Remission was observed in
32 and 25 patients at week 16/20 and 32. Ten and 9 patients
had active disease at week 16/20 and 32. Sixteen patients
colonoscopy for colorectal cancer (CRC) screening.
Introduction : Polyps or tumors are frequently found during 32 and 25 patients at week 16/20 and 32. Ten and 9 patients
Aims: The aim of our present study was to compare the
colonoscopy for colorectal cancer (CRC) screening. had active disease at week 16/20 and 32. Sixteen patients
received systemic corticosteroid at the time of UST induction,
received systemic corticosteroid at the time of UST induction,
polyp and tumor detection rates of screening and
Aims: The aim of our present study was to compare the during the maintenance therapy 6 and 4 patients received
systemic corticosteroid at week 16/20 and 32. None of the
colonoscopies performed for abdominal symptoms or fecal
polyp and tumor detection rates of screening and during the maintenance therapy 6 and 4 patients received
colonoscopies performed for abdominal symptoms or fecal systemic corticosteroid at week 16/20 and 32. None of the
occult blood test positivity outside the screening program.
patients reported side effects or serious infection. Serum
patients reported side effects or serious infection. Serum
Methods: We conducted a retrospective analysis from 1st UST and anti-UST antibody determination is in progress at
occult blood test positivity outside the screening program.
UST and anti-UST antibody determination is in progress at
Methods: We conducted a retrospective analysis from 1st
April 2019 till 31st December 2019. Data of screening and the time of abstract submission.
April 2019 till 31st December 2019. Data of screening and Conclusion: UST may effective in inducing clinical response
non-screening colonoscopies of the same age groups were
the time of abstract submission.
collected in a predefined database including patient Conclusion: UST may effective in inducing clinical response
non-screening colonoscopies of the same age groups were
and remission in patients with moderately to severely active
demographic data, indication and colonoscopy findings. and remission in patients with moderately to severely active
collected in a predefined database including patient
Crohn’s disease who gave inadequate response to
conventional therapy or to treatments with other biological
Polyp and tumor detection rates were calculated and
demographic data, indication and colonoscopy findings. Crohn’s disease who gave inadequate response to
agents. Results of serum UST and anti-UST concentrations
Polyp and tumor detection rates were calculated and
compared between the special patient groups. conventional therapy or to treatments with other biological
Results: During our study period 217 persons (50-70 years agents. Results of serum UST and anti-UST concentrations
will be discussed at the conference.
compared between the special patient groups.
Results: During our study period 217 persons (50-70 years will be discussed at the conference.
old) were screened and 1611 patients underwent
old) were screened and 1611 patients underwent 100. FORMALDEHID ALKALMAZÁSA IRRADIACIÓS
colonoscopy for other reasons. From the latter, 687 were in
PROCTITISBEN
colonoscopy for other reasons. From the latter, 687 were in 100. FORMALDEHID ALKALMAZÁSA IRRADIACIÓS
the same age group as the screened population. Fecal blood
test positivity outside screening was the indication for 71
Molnár T. , Nagyné B. N. , Maksa M. , Tóth A. , Keserű A. ,
the same age group as the screened population. Fecal blood PROCTITISBEN 1 1 1 1
1
1
1
1
1
test positivity outside screening was the indication for 71
1
Molnár T. , Nagyné B. N. , Maksa M. , Tóth A. , Keserű A.
1
1 1
1
patients. The polyp detection rates for screening, regular and Sendula E. , Szász Veress E. , Varga R. , Dr. Székely A. , ,
Dr. Horváth L. , Dr. Fejes R. , Prof.Dr.Izbéki F.
1
fecal positive patient groups were 73 vs. 40.1 vs. 52.1% Sendula E. , Szász Veress E. , Varga R. , Dr. Székely A. ,
patients. The polyp detection rates for screening, regular and
1
1
1 1
1
1
1
1
1. Fejér Megyei Szent György Egyetemi Oktató Kórház I.
respectively (p<0.001). Tumor detection rates for the same Dr. Horváth L. , Dr. Fejes R. , Prof.Dr.Izbéki F.
fecal positive patient groups were 73 vs. 40.1 vs. 52.1%
1
respectively (p<0.001). Tumor detection rates for the same
groups were 5.5 vs 7.3 vs 2.8% respectively (ns). No polyps 1. Fejér Megyei Szent György Egyetemi
Belgyógyászat Endoszkópos Laboratórium Oktató Kórház I.
and tumors were found in 25.3 vs 54.7% vs 47.9% (p<0.001).
groups were 5.5 vs 7.3 vs 2.8% respectively (ns). No polyps Belgyógyászat Endoszkópos Laboratórium
and tumors were found in 25.3 vs 54.7% vs 47.9% (p<0.001).
Conclusion: Significantly higher polyp detection rate was Introduction: A kismedencét érő sugárkezelést követően az
esetek 2-5%-ában súlyos idült irradiációs
found during screening colonoscopies compared to those
Conclusion: Significantly higher polyp detection rate was Introduction: A kismedencét érő sugárkezelést követően az
proctitis alakulhat ki. Ennek a leggyakoribb tünete a
procedures performed for symptoms or fecal blood positivity esetek 2-5%-ában súlyos idült irradiációs
found during screening colonoscopies compared to those
vérszékelés, ami vérszegénységet is leggyakoribb tünete a
procedures performed for symptoms or fecal blood positivity
outside screening. This outlines the importance of CRC proctitis alakulhat ki. Ennek a
vérszékelés, ami vérszegénységet is
screening. eening. This outlines the importance of CRC okozhat. Az esetek többségében a gyulladás lokálisan
outside scr
99. USTEKINUMAB THERAPY IN BIOLOGIC- okozhat. gyulladáscsökkentőkkel (5-ASA, szteroid
alkalmazott Az esetek többségében a gyulladás lokálisan
screening.
REFRACTORY CROHN’S DISEASE PATIENTS: alkalmazott Néhány makacs esetben argonplasma
USTEKINUMAB
IN
BIOLOGIC-
THERAPY
99.
szteroid
kezelhető)
gyulladáscsökkentőkkel
(5-ASA,
DISEASE
CROHN’S
REFRACTORY
CLINICAL RESPONSE AND THERAPEUTIC DRUG kezelhető) Néhány makacs esetben argonplasma
PATIENTS:
coaguláció, vagy egyéb endoszkópos vérzéscsillapítási
MONITORING
CLINICAL RESPONSE AND THERAPEUTIC DRUG coaguláció, vagy egyéb endoszkópos vérzéscsillapítási
kezelések alkalmazására kényszerülünk. Esetünkkel a
MONITORING
Molnár T. , Rutka M. , Bacsur P. , Kata D. , Földesi I. , kezelések alkalmazására kényszerülünk. Esetünkkel a
formaldehid eredményes alkalmazását mutatjuk be.
2
2
1
1
1
Methods: A vérszékelés miatt vizsgált betegünk prosztata
1 1
Molnár T. , Rutka M. , Bacsur P. , Kata D. , Földesi I. 1 2 formaldehid eredményes alkalmazását mutatjuk be.
Szántó K. , Bálint A. , Milassin A. , Bor R. , Fábián A. , ,
1
1 1
1 2
1
Szántó K. , Bálint A. 1 1 1 1 1 Methods: A vérszékelés miatt vizsgált
1 1
tumor miatt részesült sugárkezelésben 2 betegünk prosztata
Szepes Z. , Farkas K. , Milassin A. , Bor R. , Fábián A. ,
Szepes Z. , Farkas K. évvel korábban. Az endoszkópos kép idült irradiációs
1. First Department of Medicine, University of Szeged; 2.
tumor miatt részesült sugárkezelésben 2
1
1
1. First Department of Medicine, University of Szeged; 2. proctitisnek felelt meg, amit a
évvel korábban. Az endoszkópos kép idült irradiációs
Institute of Laboratory Medicine, University of Szeged
Institute of Laboratory Medicine, University of Szeged proctitisnek felelt meg, amit a
szövettani vizsgálat is megerősített. Mesalasin és budesonid
Introduction: Ustekinumab (UST), a fully humanised IgG1 szövettani vizsgálat is megerősített. Mesalasin és budesonid
hab alkalmazása ellenére vérzése ismétlődött, és ércsonkos
fekély is kialakult, melynek endoszkópos kezelése
monoclonal antibody targeting IL12/23p40, was recently
Introduction: Ustekinumab (UST), a fully humanised IgG1 hab alkalmazása ellenére vérzése ismétlődött, és ércsonkos
(adrenalinos infiltrálás és klip) megtörtént, de a vérzések
monoclonal antibody targeting IL12/23p40, was recently
approved for the treatment of moderate to severe cases of fekély is kialakult, melynek endoszkópos kezelése
transzfúziót
(adrenalinos
approved for the treatment of moderate to severe cases of
ami
ismétlődtek,
igénylő
Crohn’s disease (CD). In our department we have been using továbbra is infiltrálás és klip) megtörtént, de a vérzések
Crohn’s disease (CD). In our department we have been using
is
the UST therapy from March 2018. vérszegénységet okozott. A vérzés további endoszkópos
igénylő
továbbra
transzfúziót
ismétlődtek,
ami
Aims: Our aim is to report short-, and long-term efficacy data megoldására APC kezelést alkalmaztunk összesen 9
the UST therapy from March 2018.
vérszegénységet okozott. A vérzés további endoszkópos
Aims: Our aim is to report short-, and long-term efficacy data megoldására APC kezelést alkalmaztunk összesen
in a Hungarian cohort with prior exposure to both anti-TNF
alkalommal, de a vérzés továbbra is ismétlődött, ezért lokális 9
in a Hungarian cohort with prior exposure to both anti-TNF szteroid beöntéseket kezdtünk, ami érdemi javulást nem
and vedolizumab.
alkalommal, de a vérzés továbbra is ismétlődött, ezért lokális
Methods: This single-centre prospective study included szteroid beöntéseket kezdtünk, ami érdemi javulást nem
and vedolizumab.
eredményezett, ráadásul a beteg cukorbetegsége is
súlyosbodott. Ekkor 10 ml 4%-os formaldehidet lokálisan is
Methods: This single-centre prospective study included eredményezett, ráadásul a beteg cukorbetegsége
patients with endoscopic inflammation who were started on
UST. Patients received intravenous UST (induction), then 90 endoszkóposan instilláltunk, melyet 10 perc múlva vízzel
súlyosbodott. Ekkor 10 ml 4%-os formaldehidet lokálisan
patients with endoscopic inflammation who were started on
UST. Patients received intravenous UST (induction), then 90 endoszkóposan instilláltunk, melyet 10 perc múlva vízzel
70
70

70 Central European Journal of Gastroenterology and Hepatology
Volume 6, Supplementum 2 / November 2020